Als C, Laeng H, Cerny T, Kinser J A, Rösler H, Häusler R
Department of Nuclear Medicine, Inselspital, University of Berne, Switzerland.
Ann Oncol. 1998 Sep;9(9):1015-22. doi: 10.1023/a:1008277227111.
We report a case of a man presenting with a cervical malignant teratoma and a chondrosarcomatous rib metastasis. He was alive and free of recurrence five years and 10 months (= 70 months) after resection of the primary mass, followed by chemotherapy and subsequent resection of the rib tumor. This is the 35th patient reported in the literature and the first description in which an 'adjuvant' or primary chemotherapy was used. Previous patients with a cervical malignant teratoma, reported after lethal outcome, had survivals of one to 22 months (median nine months). In all patients with a preoperative clinical impression of an aggressive, differentiated or undifferentiated malignancy, the definite diagnosis of teratoma could only be made histologically. By analogy to germ cell tumors, the prognosis of malignant teratoma might be improved if complete excision is combined with new, adjuvant chemotherapy protocols for germ cell tumors. Lessons learned from this case are placed in the context of germ cell tumors in general and of non-gonadal malignant teratomas in particular.
我们报告一例男性患者，其患有宫颈恶性畸胎瘤并伴有软骨肉瘤性肋骨转移。在切除原发肿块、接受化疗以及随后切除肋骨肿瘤后，他存活了五年零十个月（即70个月），且无复发迹象。这是文献报道的第35例患者，也是首次描述使用“辅助”或一线化疗的病例。先前报道的宫颈恶性畸胎瘤患者，均预后不良，生存期为1至22个月（中位生存期9个月）。在所有术前临床诊断为侵袭性、分化型或未分化型恶性肿瘤的患者中，畸胎瘤的明确诊断只能通过组织学检查来确定。与生殖细胞肿瘤类似，如果将完整切除与针对生殖细胞肿瘤的新辅助化疗方案相结合，恶性畸胎瘤的预后可能会得到改善。从该病例中吸取的经验教训将置于一般生殖细胞肿瘤，特别是非性腺恶性畸胎瘤的背景下进行探讨。
